Press "Enter" to skip to content



[11/17/16]  Within the first year of life, the CDC recommends that children receive a total of 29 vaccinations, many of which contain the adjuvant aluminum, a substance used in vaccinations to increase the immune response to the antigen (the component of the vaccine that stimulates the immune system to make antibodies). [1]

According to Professor Christopher Exley’s recent research, there are currently two main aluminum adjuvants commonly used in vaccinations today. These are AlHydrogel, a semi-crystalline (boehmite) form of aluminium oxyhydroxide and AdjuPhos, an amorphous salt of aluminium hydroxyphosphate. The sulphate salt of the latter is also listed as being one component of an adjuvant system used in vaccinations against HPV. AlHydrogel™ and AdjuPhos™ are commonly referred to as clinically-approved aluminum adjuvants, and yet this is not the case.

There are no aluminum adjuvants that have been approved for intramuscular or subcutaneous injection into humans. There are no requirements for their approval; they are only “approved” as part of vaccine preparations.

His words are extremely worrying, especially when you consider just how many vaccinations on the childhood vaccination schedule contain the adjuvant aluminum as an ingredient.

In a press release, describing Professor Exley’s latest paper, the founder of the Dwoskin Family Foundation, Mrs. Claire Dwoskin wrote:

“Research at Keele University led by Professor Christopher Exley aims to understand the toxicity of aluminum adjuvants in vaccinations and their latest findings are now published in Nature’s ‘Scientific Reports.

In a project funded by the Medical Research Council (MRC) and the Dwoskin Foundation the group at Keele investigated the relationship between the physicochemical properties of aluminum adjuvants and the immune response. Specifically, they show that the reaction of the aluminum adjuvant at the injection site will determine its subsequent fate and therefore its activity both at the injection site and away from the injection site.

One form of aluminum adjuvant which is most commonly used in vaccines is an aluminum hydroxyphosphate salt and is more toxic at the injection site than the second form of aluminum adjuvant, also commonly used in vaccines, aluminum oxyhydroxide salt. However, the latter is more easily loaded into immune reactive cells with the possibility to be transported throughout the body. It is suggested by the Keele research that this loading of aluminum into viable cells offers a mechanism whereby significant amounts of aluminum, a known neurotoxin, might be translocated throughout the body and even across the blood brain barrier and into the central nervous system.” [2, 3, 4]

Countless Childhood Vaccinations Contain Aluminum

According to the CDC’s Vaccine Excipient & Media Summary -Excipients Included in U.S. Vaccines by Vaccine, many of the childhood vaccinations used today include an aluminum adjuvant. However, there are two six-in-one vaccinations that are not listed by the CDC that contain an aluminium adjuvant that have been extremely problematic from the beginning. These are the Infanrix Hexa and Hexavac vaccines. [5, 6, 7]

Authors of Vaccine Studies State One Thing but Mean Another

In 2011, Giuseppe Traversa and his team wrote a study titled Sudden unexpected deaths and vaccinations during the first two years of life in Italy: a case series study, which, at the time, was considered to be a success. [8]

Studying the incidence of sudden infant death after hexavalent vaccinations in Germany and Italy, the team concluded that their findings were globally reassuring. However, after reading the study in depth, it appears that the team’s outcome was anything but reassuring.

In their abstract, the team stated:

“The signal of an association between vaccination in the second year of life with a hexavalent vaccine and sudden unexpected deaths (SUD) in the two days following vaccination was reported in Germany in 2003. A study to establish whether the immunisation with hexavalent vaccines increased the short term risk of SUD in infants was conducted in Italy.”

In their introduction, they stated:

“Most deaths occurring during the first two years of life are attributable to defined causes, mainly represented by congenital malformations, malignancies, and accidents. The events in otherwise apparently healthy subjects, without any evident cause for the death, are classified as SIDS (Sudden Infant Death Syndrome) during the first year of life and SUD (Sudden Unexpected Deaths) at older ages.

In 2003 the suspicion of a possible association between the immunisation with a hexavalent vaccine (Hexavac) and the occurrence of SUD was raised in Germany. The signal was based on the observation of three deaths occurring between November 2000 and June 2003 in toddlers in their second year of life within 48 hours following the administration of the fourth dose. No signal was detected for vaccinations administered during the first year of life.

Two hexavalent products were licensed in the European Union through a centralised licensure procedure in the year 2000: Hexavac (by Aventis Pasteur MSD) and Infanrix hexa (by Glaxo SmithKline Biologicals). These combined vaccines contained antigens to immunise against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and haemophilus influenzae type b. Since licensure the two vaccines were extensively used in some EU countries (e.g., Germany, Italy, Austria).” (emphasis added)